The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial.

Schizophrenia is characterized by persistent cognitive deficits that significantly impact functional outcomes. Despite the current available treatments, these deficits remain inadequately addressed, highlighting the need to explore the effect of more novel treatments on cognition. The current study examined the effect of intranasal oxytocin on cognitive functioning in people with schizophrenia by utilizing data from a 12-week, randomized controlled trial. Sixty-seven participants with schizophrenia or schizoaffective disorder were randomized to receive placebo or intranasal oxytocin. Participants completed a comprehensive neuropsychological battery at baseline and 12 weeks. The results demonstrated that intranasal oxytocin did not significantly improve cognition in people with schizophrenia compared to placebo. These findings suggest that oxytocin does not worsen or enhance cognition in people with schizophrenia. Yet, the current intervention did not standardize the timing of cognitive assessments relative to the timing of oxytocin administration, which may explain our findings. Future studies attempting to clarify this relationship would benefit from employing a more controlled approach to the timing of treatment and assessments.

Impaired mnemonic discrimination in children and adolescents at risk for schizophrenia.

People with schizophrenia and their high-risk, first-degree relatives report widespread episodic memory impairments that are purportedly due, at least in part, to failures of mnemonic discrimination. Here, we examined the status of mnemonic discrimination in 36 children and adolescents (aged 11-17 years) with and without familial risk for schizophrenia by employing an object-based recognition task called the Mnemonic Similarity Task (MST). The MST assesses the ability to discriminate between studied images and unstudied images that are either perceptually similar to studied images or completely novel. We compared 16 high-risk, unaffected first-degree relatives of people with schizophrenia, bipolar disorder, and/or schizoaffective disorder to 20 low-risk, control participants. High-risk participants showed worse mnemonic discrimination than low-risk participants, with no difference in recognition memory or perceptual discrimination. Our findings demonstrate that mnemonic discrimination deficits previously observed in people with schizophrenia are also present in their young, high-risk, first-degree relatives.

Episodic memory impairment in children and adolescents at risk for schizophrenia: A role for context processing.

People with schizophrenia experience episodic memory impairments that have been theorized to reflect deficits in processing context (e.g., spatio-temporal features tied to a specific event). Although past research has reported episodic memory impairments in young people at-risk for schizophrenia, the extent to which these impairments reflect context processing deficits remains unknown. We addressed this gap in the literature by examining whether children and adolescents at risk for schizophrenia exhibit context processing deficits during free recall, a memory task with high contextual demands. Our sample included three groups (N = 58, 9-16 years old) varying in risk for schizophrenia:16 high-risk, unaffected first-degree relatives of patients with schizophrenia, bipolar disorder, and/or schizoaffective disorder, 22 clinical control participants with a comorbid disorder (ADHD and/or an anxiety disorder), and 20 healthy control participants. Participants first completed a free recall task and then completed a recognition memory task. Based on established theories of episodic memory, we assumed that context processing played a more pivotal role in free recall than recognition memory. Consequently, if schizophrenia risk is associated with context processing deficits, then memory impairment should be present in free recall measures that are most sensitive to context processing (i.e., recall accuracy and temporal contiguity). Consistent with this prediction, free recall accuracy and temporal contiguity were lower for the high-risk group than the healthy controls, whereas recognition memory was comparable across groups. These findings suggest that episodic memory impairments associated with schizophrenia in unaffected, first-degree relatives may reflect context processing deficits.

Valuing emotional control in social anxiety disorder: A multimethod study of emotion beliefs and emotion regulation.

This study examines relationships between emotion beliefs and emotion regulation strategy use among people with social anxiety disorder (SAD) and a psychologically healthy control group. Using experience-sampling methodology, we tested group differences in 2 types of emotion beliefs (emotion control values and emotion malleability beliefs) and whether emotion beliefs predicted trait and daily use of cognitive reappraisal and emotion suppression. People with SAD endorsed higher emotion control values and lower emotion malleability beliefs than did healthy controls. Across groups, emotion control values were positively associated with suppression (but unrelated to reappraisal), and emotion malleability beliefs were negatively associated with suppression and positively associated with reappraisal. We also addressed 2 exploratory questions related to measurement. First, we examined whether trait and state measures of emotion regulation strategies were related to emotion control values in different ways and found similar associations across measures. Second, we examined whether explicit and implicit measures of emotion control values were related to daily emotion regulation strategy use in different ways-and found that an implicit measure was unrelated to strategy use. Results are discussed in the context of growing research on metaemotions and the measurement of complex features of emotion regulation. (PsycInfo Database Record (c) 2021 APA, all rights reserved).